Intervention Review

You have free access to this content

Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men

  1. Alison Avenell1,*,
  2. Jenson CS Mak2,
  3. Dianne O'Connell3

Editorial Group: Cochrane Bone, Joint and Muscle Trauma Group

Published Online: 14 APR 2014

Assessed as up-to-date: 1 JUN 2013

DOI: 10.1002/14651858.CD000227.pub4


How to Cite

Avenell A, Mak JCS, O'Connell D. Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men. Cochrane Database of Systematic Reviews 2014, Issue 4. Art. No.: CD000227. DOI: 10.1002/14651858.CD000227.pub4.

Author Information

  1. 1

    University of Aberdeen, Health Services Research Unit, Health Sciences Building, Aberdeen, UK

  2. 2

    Gosford Hospital, Department of Aged Care and Rehabilitation, Gosford, New South Wales (NSW), Australia

  3. 3

    Cancer Council, Cancer Research Division, Sydney, NSW, Australia

*Alison Avenell, Health Services Research Unit, Health Sciences Building, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD, UK. a.avenell@abdn.ac.uk.

Publication History

  1. Publication Status: New search for studies and content updated (conclusions changed)
  2. Published Online: 14 APR 2014

SEARCH

[Figure 1]
Figure 1. tudy flow diagram for the updated search (December 2012)
[Figure 2]
Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies
[Figure 3]
Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included study
[Figure 4]
Figure 4. Funnel plot of comparison: 1 Vitamin D [D2, D3 or 25(OH)D] versus control or placebo, outcome: 1.1 Persons sustaining new hip fracture
[Figure 5]
Figure 5. Funnel plot of comparison: 1 Vitamin D [D2, D3 or 25(OH)D] versus control or placebo, outcome: 1.4 Persons sustaining any new fracture
[Analysis 1.1]
Analysis 1.1. Comparison 1 Vitamin D [D2, D3 or 25(OH)D] versus control or placebo, Outcome 1 Persons sustaining new hip fracture.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Vitamin D [D2, D3 or 25(OH)D] versus control or placebo, Outcome 2 Persons sustaining new non-vertebral fracture.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Vitamin D [D2, D3 or 25(OH)D] versus control or placebo, Outcome 3 Persons sustaining new vertebral fracture or deformity.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Vitamin D [D2, D3 or 25(OH)D] versus control or placebo, Outcome 4 Persons sustaining any new fracture.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Vitamin D [D2, D3 or 25(OH)D] plus calcium versus calcium, Outcome 1 Persons sustaining new hip fracture.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Vitamin D [D2, D3 or 25(OH)D] plus calcium versus calcium, Outcome 2 Persons sustaining new non-vertebral fracture.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Vitamin D [D2, D3 or 25(OH)D] plus calcium versus calcium, Outcome 3 Persons sustaining new vertebral fracture.
[Analysis 2.4]
Analysis 2.4. Comparison 2 Vitamin D [D2, D3 or 25(OH)D] plus calcium versus calcium, Outcome 4 Persons sustaining any new fracture.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Vitamin D [D2, D3 or 25(OH)D] versus calcium, Outcome 1 Persons sustaining new hip fracture.
[Analysis 3.2]
Analysis 3.2. Comparison 3 Vitamin D [D2, D3 or 25(OH)D] versus calcium, Outcome 2 Persons sustaining new non-vertebral fracture.
[Analysis 3.3]
Analysis 3.3. Comparison 3 Vitamin D [D2, D3 or 25(OH)D] versus calcium, Outcome 3 Persons sustaining new vertebral fracture or deformity.
[Analysis 3.4]
Analysis 3.4. Comparison 3 Vitamin D [D2, D3 or 25(OH)D] versus calcium, Outcome 4 Persons sustaining any new fracture.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Vitamin D [D2, D3 or 25(OH)D] plus calcium versus control or placebo, Outcome 1 Persons sustaining new hip fracture.
[Analysis 4.2]
Analysis 4.2. Comparison 4 Vitamin D [D2, D3 or 25(OH)D] plus calcium versus control or placebo, Outcome 2 Persons sustaining new hip fracture: subgroup analysis by residential status (institution vs community).
[Analysis 4.3]
Analysis 4.3. Comparison 4 Vitamin D [D2, D3 or 25(OH)D] plus calcium versus control or placebo, Outcome 3 Persons sustaining new non-vertebral fracture.
[Analysis 4.4]
Analysis 4.4. Comparison 4 Vitamin D [D2, D3 or 25(OH)D] plus calcium versus control or placebo, Outcome 4 Persons sustaining new vertebral fracture.
[Analysis 4.5]
Analysis 4.5. Comparison 4 Vitamin D [D2, D3 or 25(OH)D] plus calcium versus control or placebo, Outcome 5 Persons sustaining any new fracture.
[Analysis 4.6]
Analysis 4.6. Comparison 4 Vitamin D [D2, D3 or 25(OH)D] plus calcium versus control or placebo, Outcome 6 Persons sustaining any new fracture: subgroup analysis by residential status (institution vs community).
[Analysis 5.1]
Analysis 5.1. Comparison 5 Alfacalcidol [1-alpha(OH)D3] versus control or placebo, Outcome 1 Persons sustaining new hip fracture.
[Analysis 5.2]
Analysis 5.2. Comparison 5 Alfacalcidol [1-alpha(OH)D3] versus control or placebo, Outcome 2 Persons sustaining new non-vertebral fracture.
[Analysis 5.3]
Analysis 5.3. Comparison 5 Alfacalcidol [1-alpha(OH)D3] versus control or placebo, Outcome 3 Persons sustaining new vertebral fracture.
[Analysis 6.1]
Analysis 6.1. Comparison 6 Alfacalcidol [1-alpha(OH)D3] plus calcium versus calcium, Outcome 1 Persons sustaining new hip fracture.
[Analysis 6.2]
Analysis 6.2. Comparison 6 Alfacalcidol [1-alpha(OH)D3] plus calcium versus calcium, Outcome 2 Persons sustaining new vertebral deformity.
[Analysis 7.1]
Analysis 7.1. Comparison 7 Alfacalcidol [1-alpha(OH)D3] versus calcium, Outcome 1 Persons sustaining new vertebral deformity.
[Analysis 8.1]
Analysis 8.1. Comparison 8 Calcitriol [1,25(OH)2D3] versus control or placebo, Outcome 1 Persons sustaining new hip fracture.
[Analysis 8.2]
Analysis 8.2. Comparison 8 Calcitriol [1,25(OH)2D3] versus control or placebo, Outcome 2 Persons sustaining new non-vertebral fracture.
[Analysis 8.3]
Analysis 8.3. Comparison 8 Calcitriol [1,25(OH)2D3] versus control or placebo, Outcome 3 Persons sustaining new vertebral deformity.
[Analysis 9.1]
Analysis 9.1. Comparison 9 Calcitriol [1,25(OH)2D3] plus calcium versus calcium, Outcome 1 Persons sustaining new non-vertebral fracture.
[Analysis 9.2]
Analysis 9.2. Comparison 9 Calcitriol [1,25(OH)2D3] plus calcium versus calcium, Outcome 2 Persons sustaining new vertebral deformity.
[Analysis 10.1]
Analysis 10.1. Comparison 10 Calcitriol [1,25(OH)2D3] plus vitamin D plus calcium versus vitamin D plus calcium, Outcome 1 Persons sustaining new vertebral deformity.
[Analysis 11.1]
Analysis 11.1. Comparison 11 Calcitriol [1,25(OH)2D3] versus calcium, Outcome 1 Persons sustaining new non-vertebral fracture.
[Analysis 11.2]
Analysis 11.2. Comparison 11 Calcitriol [1,25(OH)2D3] versus calcium, Outcome 2 Persons sustaining new vertebral deformity.
[Analysis 11.3]
Analysis 11.3. Comparison 11 Calcitriol [1,25(OH)2D3] versus calcium, Outcome 3 Persons sustaining new vertebral deformity in Tilyard study.
[Analysis 12.1]
Analysis 12.1. Comparison 12 Calcitriol [1,25(OH)2D3] versus vitamin D (with or without calcium in each group), Outcome 1 Persons sustaining new non-vertebral fracture.
[Analysis 12.2]
Analysis 12.2. Comparison 12 Calcitriol [1,25(OH)2D3] versus vitamin D (with or without calcium in each group), Outcome 2 Persons sustaining new vertebral deformity.
[Analysis 13.1]
Analysis 13.1. Comparison 13 Vitamin D [D2, D3 or 25(OH)D] or any analogue with/without calcium: adverse effects, Outcome 1 Deaths.
[Analysis 13.2]
Analysis 13.2. Comparison 13 Vitamin D [D2, D3 or 25(OH)D] or any analogue with/without calcium: adverse effects, Outcome 2 Persons with hypercalcaemia.
[Analysis 13.3]
Analysis 13.3. Comparison 13 Vitamin D [D2, D3 or 25(OH)D] or any analogue with/without calcium: adverse effects, Outcome 3 Persons with gastrointestinal effects.
[Analysis 13.4]
Analysis 13.4. Comparison 13 Vitamin D [D2, D3 or 25(OH)D] or any analogue with/without calcium: adverse effects, Outcome 4 Persons with renal disease (calculi or insufficiency).